GSK
GlaxoSmithKline PLC
50.50$
+0.3%
vs. previous close
Closing price · As of: Aug 13, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 34.9% | 31.6% | 29.4% | 28.9% | 29.8% | 28.6% | 29.8% | 29.8% | 29.1% | 28.6% | 28.3% | 28.4% | |
| 5.2% | 5.0% | 4.8% | 5.1% | 5.5% | 6.2% | 7.4% | 6.1% | 5.4% | 5.6% | 5.5% | 5.0% | |
| 11.0% | 8.8% | 7.0% | 5.1% | 5.5% | 6.2% | 7.4% | 6.1% | 5.4% | 5.6% | 5.5% | 5.0% | |
| 14.6% | 12.5% | 12.5% | 13.4% | 12.7% | 10.1% | 12.4% | 13.0% | 13.5% | 12.7% | 12.6% | 13.1% | |
| 9.0% | 9.3% | 9.7% | 10.1% | 10.2% | 9.5% | 9.9% | 10.2% | 10.0% | 9.7% | 9.8% | 10.2% | |
| 12.7% | – | – | – | 16.8% | 16.9% | 12.7% | 12.2% | 12.3% | 16.5% | – | – | |
| 11.5% | 11.5% | 11.9% | 12.0% | 11.5% | 11.7% | 11.4% | 11.4% | 11.6% | 11.5% | 11.6% | 12.0% | |
| 25.1% | 25.0% | 26.8% | 26.6% | 25.9% | 26.1% | 26.8% | 25.9% | 27.5% | 27.4% | 28.9% | 27.2% | |
| 79.3% | 78.3% | 77.4% | 76.3% | 76.8% | 78.0% | 77.5% | 75.8% | 74.3% | 73.8% | 72.3% | 72.2% | |
| 36.8% | 35.7% | 33.9% | 35.0% | 37.0% | 36.5% | 34.3% | 34.4% | 34.8% | 35.0% | 35.7% | 34.9% | |
| 8.0% | 4.8% | 4.5% | 5.8% | 4.8% | 4.0% | 3.2% | 3.5% | 4.7% | 4.9% | 8.0% | 7.0% | |
| 25.6% | 26.9% | 25.0% | 24.5% | 24.8% | 5.8% | 25.0% | 25.0% | 19.0% | 25.2% | 22.8% | 23.2% | |
| 21.5% | 18.8% | – | – | 22.8% | 23.0% | 21.0% | 18.8% | 18.0% | 24.1% | – | – | |
| 21.6% | 22.6% | 23.7% | 24.8% | 24.1% | 23.0% | 23.3% | 25.0% | 26.3% | 26.8% | 28.4% | 28.6% | |
| 11.5% | 12.3% | 13.6% | 14.8% | 14.1% | 13.1% | 13.7% | 14.8% | 16.3% | 16.7% | 18.4% | 18.6% | |
| 2.8% | 2.7% | 2.8% | 2.8% | 3.5% | 3.5% | 2.6% | 2.5% | 2.5% | 3.3% | 2.5% | 3.3% |
Data as of: August 13, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.